In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine 4 receptor agonist, in patients with severe chronic constipation.

The Appraisal Committee considered evidence submitted by the manufacturer of prucalopride and a review of this submission by the Evidence Review Group (ERG). The manufacturer described 9 trials that ...

Prucalopride, a serotonin-4 receptor agonist, is indicated for the treatment of chronic idiopathic constipation in adults. The first generic version of Motegrity ® has been approved by the Food ...

ANI Pharmaceuticals, Inc. announced the launch of its Prucalopride Tablets, a generic version of the drug Motegrity®, following final FDA approval of their Abbreviated New Drug Application.

Motegrity (prucalopride) is a prescription drug that’s used to treat chronic idiopathic constipation. Motegrity can cause side effects that range from mild to serious. Examples include headache ...

Discover comprehensive details about Prucalopride, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

The Food and Drug Administration (FDA)’s Gastrointestinal Drugs Advisory Committee voted in favor (10 to 0) of approving prucalopride for the treatment of chronic idiopathic constipation (CIC ...

ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity ®. "We are delighted to build momentum early in 2025 with the approval of the first generic for ...

Review the side-effects of Prucalopride as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority ...

Limited treatments currently exist, but studies in animals and humans have pointed to drugs such as the laxative prucalopride that activate serotonin receptors as a potential therapeutic for the ...

4 Consideration of the evidence 4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of prucalopride, having considered evidence on the nature of chronic ...